Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2004

View Archived Issues

Eisai assumes distribution responsibilities for Aciphex

Kyorin Pharmaceutical to tie up with ActivX Bioscience

BioPort signs contract to supply anthrax vaccine

Dyax and Baxter to collaborate in MIF antibody research

Innovative Companies files patent for method to stabilize levothyroxine

KaloBios and Celscia Therapeutics close merger

Morphotek and NCI sign agreement to develop antibodies for the treatment of various cancers

Amgen claims two series of calcium channel modulators for bone and PTH disorders

JT team presents MTP inhibitors devoid of hepatic side effects

New etonogestrel esters and their use presented by Akzo Nobel scientists

Novel factor Xa inhibitors prepared and tested at Boehringer Ingelheim

New adenosine A3 ligands jointly reported by Solvay and ArQule

Lilly claims new opioid antagonists with utility in obesity and related disorders

Novel protein kinase inhibitors for cancer and neurological disorders

Phase Ib trial evaluates WX-UK1 in head and neck cancer patients

Phase II trial design agreed for InKine's new generation purgative product

Phase I/II HGTV43 gene construct study commences

Pivotal Fibrillex study cleared to continue by DSMB

Axcan submits sNDA for 1g mesalamine suppository

Zyprexa approved for maintenance in bipolar disorder treatment

Remoxy advances into phase I

New expanded indication for Lamictal

Chiron HIV vaccine enters phase I trial

Procleix Ultrio Assay receives European CE Mark

Phase I inhaled doripenem trial commences enrollment

Improved survival found with Provenge(R) in patients with advanced prostate cancer

Significant improvements induced by renzapride in IBS

Dalbavancin reported more effective than vancomycin against catheter-related bloodstream infections

Evidence of antifungal activity found for Thymus essential oils

Topical imiquimod found safe and effective in squamous cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...